BARRY JAMES
Known title: EVP, President, LSGCIK: 0002022345
Associated companies
Transaction History
| BIO | ▲ Buy | Option Exercise | 1,056 | $0 | 9/6/2026 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 470 | $181K | 9/6/2026 | View on chart |
| BIO | ▲ Buy | Option Exercise | 1,027 | $0 | 9/5/2026 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 369 | $142K | 9/5/2026 | View on chart |
| BIO | ▲ Buy | Option Exercise | 425 | $0 | 9/1/2026 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 154 | $59K | 9/1/2026 | View on chart |
| BIO | ▼ Sell | Open Market | 700 | $214K | 11/6/2025 | View on chart |
| BIO | ▲ Buy | Option Exercise | 1,056 | $0 | 9/6/2025 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 378 | $112K | 9/6/2025 | View on chart |
| BIO | ▲ Buy | Option Exercise | 602 | $0 | 9/1/2025 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 217 | $65K | 9/1/2025 | View on chart |
| BIO | ▼ Sell | Open Market | 623 | $206K | 9/4/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 217 | $0 | 9/3/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 78 | $26K | 9/3/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 265 | $0 | 9/2/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 95 | $32K | 9/2/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 250 | $0 | 9/1/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 90 | $30K | 9/1/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 173 | $0 | 9/1/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 62 | $21K | 9/1/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 177 | $0 | 9/1/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 64 | $22K | 9/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth
The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth. The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.